GC GC Holdings
A Game Changer in Global Total Health Care
The GC Group leading the digital healthcare industry
based on its strong pharmaceutical foundation.
more
The GC Group leading the digital healthcare industry
based on its strong pharmaceutical foundation.
Dreaming of a world where humanity no longer must suffer from disease and illnesses,
the GC Group is taking large strides as a global leader in the health industry rising above
and beyond the scope of a domestic health care company.
With a total of 40 affiliates at home and abroad (25 domestic, 15 overseas), the GC
Group delegates the management of the entire Group operations, including strategic
direction, new business creation, and portfolio management to the GC Holdings
company, while each affiliate takes charge of the manufacturing and sales of special
medicine and digital healthcare business.
GC Group is a biotech-based global total healthcare group that encompasses products
and services such as disease prevention, diagnosis, treatment, medical devices, and
healthcare.
the GC Group is taking large strides as a global leader in the health industry rising above
and beyond the scope of a domestic health care company.
With a total of 40 affiliates at home and abroad (25 domestic, 15 overseas), the GC
Group delegates the management of the entire Group operations, including strategic
direction, new business creation, and portfolio management to the GC Holdings
company, while each affiliate takes charge of the manufacturing and sales of special
medicine and digital healthcare business.
GC Group is a biotech-based global total healthcare group that encompasses products
and services such as disease prevention, diagnosis, treatment, medical devices, and
healthcare.
Shortcut
GC MS started as a part of GC's diagnostic project in 1972 and it launched the first AIDS diagnostic reagent GENEDIA HIV1/2 ELISA in Korea in 1987, to contribute to the improvement of national health. Over the past 50 years, the company has focused on R&D in various fields such as molecular diagnosis, immunology, hematology, and POCT and formed a portfolio such as in vitro diagnostic reagent/device, home medical device, hemodialysis solutions, and blood sugar management systems.
GC MS is growing as a global medical device company that creates a healthy company, healthy people, and a healthy world based on its advanced technology built over 50 years.
GC MS is growing as a global medical device company that creates a healthy company, healthy people, and a healthy world based on its advanced technology built over 50 years.
GC Genome provides clinical genetic testing services necessary for the medical field, focusing on cancer, rare genetic diseases, prenatal care, newborns, health checkups, microbiomes, and clinical trial sample analysis institutions.
As a leading company in the field of clinical genomic analysis in Korea, we will continue to lead by example, widening the gap from others based on advanced technology and will grow into a global company that is also acknowledged overseas.
As a leading company in the field of clinical genomic analysis in Korea, we will continue to lead by example, widening the gap from others based on advanced technology and will grow into a global company that is also acknowledged overseas.
GCCL is a specialized clinical trial test analysis company that provides analysis services for the entire process of a clinical trial. It has a platform optimized for clinical trials based on global quality standards of GCLP qualification, operates its own sample transportation logistics system, and provides clinical trial sample analysis services that can meet customer needs. GCCL's goal is to grow beyond Korea to become a trusted company that supports successful clinical trials for Asia and global partners.
GC Labs started as a medical institution specializing in clinical tests in 1982, and it has strategic partnerships with the world's leading clinical testing related institutions. It has been working on open innovation and differentiation, including the introduction of high-tech equipment and training of excellent R&D personnel based on specialized tests at university-level hospitals.
At our cutting edge clinical examination center with a floor space of 12,000m2 designed as the first clinical examination building in Korea, we are conducting safe and reliable tests for our clinical trials. In 2008, it was the first trustee to obtain the IS09001 Quality Management System and ISO14001 Environmental Management System Certifications.
The GC Labs' inspection room uses a cutting-edge complete automation system to quickly and accurately perform some 4,000 tests annually, 24 hours a day, and conducts the largest number of special tests in Korea.
At our cutting edge clinical examination center with a floor space of 12,000m2 designed as the first clinical examination building in Korea, we are conducting safe and reliable tests for our clinical trials. In 2008, it was the first trustee to obtain the IS09001 Quality Management System and ISO14001 Environmental Management System Certifications.
The GC Labs' inspection room uses a cutting-edge complete automation system to quickly and accurately perform some 4,000 tests annually, 24 hours a day, and conducts the largest number of special tests in Korea.
The company was was established as a POCT (point of care testing) company based on IT and Bio convergence technology in mobile healthcare and in vitro diagnostics under the motto of "Bio-IT technology for human, We find the answers from a drop of blood."
GC Medis focuses on the POCT product line, developing biosensors for blood sugar, hemoglobin, lactic acid measurement, HbA1c measurement analyzers, and measurement reagent based on differentiated patent technologies.
We will strengthen our product competitiveness, quality stability, and production management based on active R&D investment and the best production facilities, to become the leading diagnostic company.
GC Medis focuses on the POCT product line, developing biosensors for blood sugar, hemoglobin, lactic acid measurement, HbA1c measurement analyzers, and measurement reagent based on differentiated patent technologies.
We will strengthen our product competitiveness, quality stability, and production management based on active R&D investment and the best production facilities, to become the leading diagnostic company.
Geneslab produces finished products and raw materials based on its R&D capabilities, and has the industry leading enzyme production and optimization technology.
The ultimate goal is to contribute to human health by creating the best products and services based on human talent and technology.
The ultimate goal is to contribute to human health by creating the best products and services based on human talent and technology.